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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.003Adhesion molecule CD44 is expressed by multiple cell types and is implicated in various cellular and
immunological processes. In this study, we examined the effect of global CD44 deﬁciency on myelin
oligodendrocyte glycoprotein peptide (MOG)-induced experimental autoimmune encephalomyelitis
(EAE), a murine model of multiple sclerosis. Compared to C57BL/6 wild-type mice, CD44-deﬁcient
mice presented with greater disease severity, increased immune cell numbers in the central nervous
system, and increased anti-MOG antibody and proinﬂammatory cytokine production, especially those
associated with T helper 17 (Th17) cells. Further, decreased numbers of peripheral CD4þCD25þFoxP3þ
regulatory T cells (Tregs) were observed in CD44-knockout mice throughout the disease course. CD44-
knockout CD4 T cells exhibited reduced transforming growth factor-b receptor type I (TGF-b RI)
expression that did not impart a defect in Treg polarization in vitro, but did correlate with enhanced
Th17 polarization in vitro. Further, EAE in bone marrowechimeric animals suggested CD44 expression
on both circulating and noncirculating cells limited disease severity. Endothelial expression of CD44
limited T-cell adhesion to and transmigration through murine endothelial monolayers in vitro.
Importantly, we also identiﬁed increased permeability of the bloodebrain barrier in vivo in CD44-
deﬁcient mice before and following immunization. These data suggest that CD44 has multiple
protective roles in EAE, with effects on cytokine production, T-cell differentiation, T-celleendothelial
cell interactions, and bloodebrain barrier integrity. (Am J Pathol 2013, 182: 1322e1336; http://
dx.doi.org/10.1016/j.ajpath.2013.01.003)Supported in part by US Public Health Service grants R37-HL28373,
RO1-HL51018, and a Reed Foundation grant (J.A.M.) and by NIH grants
T32 GM007223 and T32 DK07556 (K.M.F.).Multiple sclerosis (MS) is an autoimmune, demyelinating
disease resulting from chronic inﬂammation in the central
nervous system (CNS). Experimental autoimmune encepha-
lomyelitis (EAE), the primary and long-used animal model of
MS, produces immune processes relevant to the human
disease.1 The progression and pathogenesis of EAE is
complex and depends onmultiple cell types and processes.2e4
T helper 17 (Th17) cells and their distinctive cytokine, IL-
17, play pivotal roles in EAE/MS pathogenesis.5e7 Th17
cells, members of a CD4 T-cell effector subset, are gener-
ated from naive CD4 T-cell precursors in response to
cytokines TGF-b and IL-6, whereas IL-23 expands this
population and increases pathogenicity.8,9 In EAE, Th17stigative Pathology.
.cells ﬁrst inﬁltrate and initiate recruitment to the CNS,5,6
and Th17-produced IL-17 induces neuronal death6 and
increases permeability of the bloodebrain barrier (BBB),
allowing continued inﬂux of immune cells by disrupting
endothelial cell (EC) junctions.6,10
Regulatory T cells (Tregs), the primary suppressors of the
immune system, play a pivotal role in EAE that is opposite
to Th17 cells. Treg depletion exacerbates disease symptoms,
whereas supplementation with additional Tregs ameliorates
Anti-Inﬂammatory Role of CD44 in EAEthe disease.11,12 Identiﬁed by the expression pattern
CD4þCD25þFoxP3þ, Tregs are generally divided into two
principal subsets: naturally occurring Tregs, which arise in
the thymus during development, and induced Tregs (iTregs),
which can be generated in the periphery from naive CD4 T
cells in response to TGF-b.13,14
Vascular EC also contribute to the complex pathogenesis of
EAE. EC regulate leukocyte adhesion and extravasation,
maintain vascular integrity, and limit injury and immune-
mediated vascular permeability. The CNS vasculature, the
primary constituent of theBBB, is especially unique and plays
a critical role in protecting the CNS microenvironment. In
MS/EAE, there is a characteristic breakdown of the BBB
followed by accumulation of inﬂammatory inﬁltrates.15,16
CD44, a ubiquitously expressed type I transmembrane
glycoprotein, has been implicated in a wide variety of
cellular processes within and outside of the immune sys-
tem.17,18Alternative splicing and multiple posttranslational
modiﬁcations generate various structural and functional
versions of CD44 and are thought to be responsible for its
large range of diverse and sometimes seemingly contradic-
tory cellular functions.
Although CD44 has been studied in several immunological
contexts as a positive or negative regulator of inﬂammation, the
many results are confounded by use of different mouse strains,
inﬂammatory models, and experimental approaches. CD44 has
been implicated as a proinﬂammatory molecule in several
studies that identiﬁed an anti-inﬂammatory effect of a CD44
monoclonal antibody in multiple immune-mediated processes
and diseases such as lymphocyte extravasation,19collagen- or
proteoglycan-induced arthritis, respectively,20,21 type 1 dia-
betes,22 asthma,23 andEAE.24 However, most studies in CD44-
knockout (KO) mice suggest an anti-inﬂammatory role for this
molecule in various immunological processes instead. CD44-
KO mice experience enhanced inﬂammation in several
models of pulmonary inﬂammation that suggest various roles of
CD44 in immune cell clearance, TGF-b signaling, and repres-
sion of Toll-like receptor (TLR) signaling and inﬂammatory
gene expression.25e28 Further, CD44-KOmice show increased
septic responses to lipopolysaccharide29 and enhanced inﬂam-
matory responses following myocardial infarction30 or hepatic
injury.31 CD44 deﬁciency also led to increased collagen-
induced arthritis severity with up-regulation of inﬂammatory
genes in arthritic CD44-KO T cells.32 Clearly, antibody-
mediated interference can have very different effects than
genetic disruption of CD44. Hutas et al33 in 2008 reported
disparate effects of CD44 monoclonal antibody treatment
versus CD44 deﬁciency on leukocyte recruitment during
proteoglycan-induced arthritis.
Despite antibody-mediated interference studies, the role
of CD44 in EAE/MS remains poorly understood. In active
MS lesions, there is an increase in CD44 expression and
accumulation of hyaluronan (HA), a major CD44
ligand.34,35 Previously, CD44 was shown to facilitate uptake
of HA,36 promoting resolution of tissue-injury signals and
inﬂammation.25,37 By contrast, a conditional mouse modelThe American Journal of Pathology - ajp.amjpathol.orgof oligodendrocyte-speciﬁc overexpression of CD44 found
a correlation between CD44 expression and enhanced HA
accumulation, prevention of oligodendrocyte differentiation,
and subsequent inﬂammation-independent demyelination.35
Until recently, EAE had not been examined in CD44-KO
mice. This report demonstrates that CD44-KO mice present
with increased EAE disease severity. This was associated
with loss of CD44 on circulating immune cells, and also on
noncirculating cells, speciﬁcally vascular EC of the BBB.We
illustrate a more proinﬂammatory T-cell proﬁle in CD44-KO
mice with a reduction in Treg numbers throughout the disease
that is accompanied by increased permeability of the BBB.
Further, we illustrate a previously unidentiﬁed role for CD44
in the baseline integrity of the BBB, which has far-reaching
implications beyond MS/EAE.
Materials and Methods
Mice and Reagents
C57BL/6 wild-type (WT) and CD44-KO mice (B6.129 (Cg)-
Cd44tm1Hbg/J) (The Jackson Laboratory, Bar Harbor, ME)
were housed in the animal facilities at Yale University School
ofMedicine according toYaleUniversity andNIH guidelines.
All mice were used between 8 and 10 weeks of age. Murine
MOG35e55 peptide was synthesized by the W.M. Keck
Biotechnology Resource Laboratory at Yale University (New
Haven, CT). Alexaﬂuor-conjugated secondary antibodies
were purchased from Invitrogen (Carlsbad, CA) and horse-
radish peroxidaseeconjugated secondary antibodies from
Santa Cruz Biotechnology (Santa Cruz, CA). Fluorescent-
conjugated primary antibodies anti-CD4, anti-CD25, anti-
CD45, anti-FoxP3, and antieIL-17 were purchased from
BD Bioscience (San Jose, CA). Anti-TGFbRI was purchased
from Santa Cruz Biotechnology. Anti-CD31 was generated in
house previously.38
EAE Induction
Unless otherwise stated, mice received 300 mg of rodent
MOG35e55 peptide emulsiﬁed in complete Freund’s adju-
vant containing heat-killed Mycobacterium butyricum
(Difco, Detroit, MI) via s.c. ﬂank injection on days 0 and 7;
on days 0 and 2, mice received 500 ng of pertussis toxin (List
Biological Laboratories, Campbell, CA) via i.p. injection.
The mice were monitored daily and graded for clinical
symptoms of EAE on the following basis: 0, no disease; 1,
ﬂaccid tail; 2, hind-limb weakness/unsteady gait; 3, hind-
limb paralysis; 4, hind- and fore-limb weakness/paralysis;
5, moribund. Disease index was calculated by [(sum of the
mean daily clinical scores)/(day of disease onset)]  100.
Histopathology and Immunoﬂuorescence
Mice were deeply anesthetized and perfused intracardially
with cold PBS followed by room temperature formalin1323
Flynn et al(parafﬁn sections) or cold 4% paraformaldehyde in PBS
(frozen sections). Brains and spinal cords were removed
and ﬁxed in formalin or 4% paraformaldehyde. Parafﬁn-
embedded tissues were processed, sectioned, and stained with
H&E by the Research Histology Laboratory at Yale. For
immunoﬂuorescent staining, tissues were embedded in
optimal cutting temperature compound and cut into 6-mm thin
sections for CD45 staining or 40-mm-thick sections for IgG/
CD31. Before staining, sections were washed with PBS and
blocked for 1 hour at room temperature with 1% bovine serum
albumin, 3% normal goat serum, and 0.3% Triton X-100 in
PBS. Thin sections were incubated with rat anti-CD45 (BD
Bioscience) for 2 hours at room temperature, followed by goat
anti-rat IgG conjugated to alexaﬂuor-594. Thick ﬂoating
sections were incubated with goat anti-mouse IgG conjugated
to alexaﬂuor-594 and rabbit anti-CD31 for 48 hours at 4C
followed by goat anti-rabbit IgG conjugated to alexaﬂuor-488.
Antibody Enzyme-Linked Immunosorbent Assay
For serumcollected fromWTandCD44-KOmiceduringEAE,
96-well plates were coated with 10 mg/mLMOG35e55 peptide
in PBS overnight at 4C. Serum was collected, diluted 1:1000
in PBS containing 1%bovine serumalbumin, and incubated on
MOG-coated plates for 2 hours at room temperature, followed
by anti-mouse IgG conjugated to horseradish peroxidase
secondary antibodies. Signal was visualized with tetrame-
thylbenzidine substrate and detected on a Wallac multiplate
reader (PerkinElmer Life Sciences, Shelton, CT) at 450 nm.
Isolation of CNS Mononuclear Cells
To isolate mononuclear cells from the inﬂamed CNS, mice
were deeply anesthetized and perfused intracardially with
cold RPMI. CNS tissue was removed, homogenized, incu-
bated with 1 mg/mL collagenase at 37C for 30 minutes,
and then centrifuged over a discontinuous Percoll gradient
by resuspending the resulting pellet in 3 mL of 100% Per-
coll, then layering the suspension with 2 mL of 80% Percoll,
3 mL of 40% Percoll, and 2 mL of 30% Percoll. Percoll
(100%) was made by adding 9 mL of Percoll and 1 mL of
10 PBS. All other dilutions were made from 100% Percoll
and 1 PBS. Isolated cells were counted and immediately
used for RNA extraction and cDNA preparation. CNS tissue
from six mice was pooled for each sample.
Microglial cells from individual bone marrow (BM)-
chimeric mice were isolated as previously described.39
RNA Extraction, cDNA Preparation, and Real-Time PCR
RNAwasextracted fromcells usinganRNeasyProtectMiniKit
(Qiagen, Valencia, CA) and cDNA generated from 750 ng of
RNA using an iScript cDNASynthesis Kit (Bio-Rad, Hercules,
CA) as per the manufacturer’s instructions. Real-time PCRwas
performedusing SYBRGreen Supermix (Bio-Rad) and 1mLof
cDNA per sample (each sample was run in triplicate). Ct values1324were normalized against b-actin, and data were analyzed using
the DDCt method. Validated primers were ordered from Real
Time Primers (Elkins Park, PA) with the exception of the
IL-17A and TGFbRI primers, which were synthesized by
Integrated DNA Technologies (Coralville, IA). Primer
sequences are as follows: IL-17A (forward) 50-ACCTCAA-
CCGTTCCACGTCA-30, (reverse) 50-CAGGGTCTTCAT-
TGCGGTG-30; TGFbRI (forward), 50-CATTCACCACC-
GTGTGCCAAATGA-30, (reverse) 50-ACCTGATCCAGA-
CCCTGATGTTGT 30.
T-Cell Restimulation and Cytokine Measurement
Splenocytes were isolated and cultured in RPMI supple-
mented with 10% fetal bovine serum. Splenocytes (3.5 
106) were cultured in 24-well plates with 50 mg/mL
MOG35e55, and the supernatant was collected after 72 hours.
Cytokine enzyme-linked immunosorbent assays (ELISAs)
(eBioscience, San Diego, CA) were performed as per the
manufacturer’s instructions. Each sample was completed in
triplicate.
Flow Cytometry
Splenocytes or lymph node cells from naïve or immunized
animals were prepared for ﬂuorescence-activated cell sort-
ing (FACS) as previously described.40 For Tregs, ﬁxation
and FoxP3 staining using a FoxP3 Staining Kit (eBio-
science) was performed as per the manufacturer’s instruc-
tions, using CD4 and CD25 ﬂuorescently conjugated
antibodies. For intracellular IL-17 detection, cells were
cultured for 5 hours with 50 ng/mL phorbol myristate
acetate, 500 ng/mL ionomycin (Sigma-Aldrich, St. Louis,
MO), and GolgiStop Protein Transport Inhibitor (BD
Bioscience). The cells were ﬁrst stained for surface markers,
followed by ﬁxation, permeabilization, and staining with
ﬂuorescently conjugated antieIL-17 using a Cytoﬁx/Cyto-
perm Fixation/Permeabilization Solution Kit (BD Biosci-
ence). Flow cytometric analysis was performed using
a FACSCalibur or LSR II ﬂow cytometer and FlowJo
software (all from BD Bioscience).
Cell Lysate Preparation and Western Blot Analysis
Splenic and T-cell lysates were prepared and subjected to
Western blot analysis as described previously.40
CD4 T-Cell in Vitro Polarization
Naive CD4 T cells were isolated from total splenocytes
using an EasySep Mouse CD4þ T Cell Enrichment Kit
(Stemcell Technologies, Vancouver, BC, Canada) as rec-
ommended by the manufacturer. CD4 T cells (0.75  106)
were stimulated with plate-bound anti-CD3 and soluble anti-
CD28 (BD Bioscience) at 1 mg/mL each. For Treg differ-
entiation, cells were treated with 20 ng/mL IL-2 (R&Dajp.amjpathol.org - The American Journal of Pathology
Anti-Inﬂammatory Role of CD44 in EAESystems, Minneapolis, MN) and 2 to 10 ng/mL TGF-
b (PeproTech, Rocky Hill, NJ). For Th17 differentiation,
cells were treated with 20 ng/mL IL-6 (eBioscience),
20 ng/mL IL-23 (eBioscience), 5 ng/mL TGF-b, 10 mg/mL
antieIL-4 (eBioscience), and 10 mg/mL antieinterferon
(IFN)-g (eBioscience) with or without 50 mg/mL low
molecular weight (LMW) or 50 mg/mL high molecular
weight (HMW) HA (Sigma-Aldrich). After 96 hours, cells
were prepared for FACS analysis as described above.Generation of BM Chimeras
Hematopoietic precursor transplantation was performed as
described previously.41 Brieﬂy, recipient mice were irradi-
ated twice with 5 Gy (500 rads) separated by 2 hours, using
a 137Cs irradiator. Six hours after the second irradiation,
recipient mice received 12  106 donor marrow cells retro-
orbitally. After 6 weeks, cells were harvested from chimeric
animals as described or EAE was induced.Murine BrEC Isolation and Culture
Cerebral capillary EC were isolated from brain microvessels
of 4- to 10-day-old WT and CD44-KO mice, and immortal-
ized as described previously.41Murine brain EC (BrEC) were
cultured on 1.5% gelatinecoated plates in Dulbecco’s
modiﬁed Eagle’smedium containing 10% fetal bovine serum,
2mmol/L L-glutamine, 0.1mmol/L nonessential amino acids,
1 mmol/L sodium pyruvate, 10 mmol/L HEPES, 105 mol/L
b-mercaptoethanol, 100 U/mL penicillin, and 100 mg/mL
streptomycin in 8% CO2 at 37C. Cells were used between
passages 10 and 15.Adhesion and Transendothelial Migration Assay
T-cell adhesion to EC was examined as previously
described.40 Twenty-four hours before lymphocyte addition,
the BrEC medium was changed to 1% fetal bovine serum in
Dulbecco’s modiﬁed Eagle’s medium with or without
10 ng/mL murine TNFa (PeproTech). Unstimulated or anti-
CD3/anti-CD28eactivated T cells (1  106) were added to
the BrEC monolayers in serum-free Dulbecco’s modiﬁed
Eagle’s medium and incubated at 37C for 5 hours. For
hyaluronidase treatment, BrEC were incubated with
0.5 U/mL hyaluronidase (from Streptomyces hyalurolyticus;
Sigma-Aldrich) in serum-free medium for 1 hour at 37C
before addition of T cells.
T-cell transendothelial migration was performed as
previously described using a Transwell system (BD Biosci-
ence).40 Anti-CD3/anti-CD28eactivated T cells (1.6  106)
were added to the upper well containing a conﬂuent BrEC
monolayer in serum-free Dulbecco’s modiﬁed Eagle’s
medium. T cells that migrated through the BrEC monolayer
and underlying extracellular matrix were collected from the
lower chambers at 4, 20, and 40 hours and counted.The American Journal of Pathology - ajp.amjpathol.orgIn Vivo Evans Blue Permeability Assay
In vivo permeability was measured by 4 mL/g bodyweight
retro-orbital injection of sterile 0.5% Evans Blue dye w/v in
PBS as described previously.41 One hour following the
injection of dye, mice were anesthetized, perfused intra-
cardially with cold PBS, and brains were removed. Dye was
extracted from minced brain tissue by incubating the tissue
in 5 mL/mg tissue formamide at room temperature for
72 hours. The optical density at 650 nm (OD650 nm) value
was measured for each sample, and a permeability index
was calculated by dividing the OD650 nm value for each
sample by the average OD650 nm value of tissue from three
mice that had not received dye. Skin vessel permeability
was determined similarly.
Statistical Analysis
Differences between data sets were analyzed using P values
determined using a two-tailed Student’s t-test. Error bars
represent SEM.
Results
Deletion of CD44 Results in Increased EAE Disease
Severity and Inﬂammation
To examine the effect of CD44 deﬁciency during MOG-
induced EAE, C57BL/6 WT and CD44-KO mice were
immunized with MOG35e55 peptide, and several disease
processes were characterized. First, the mice were monitored
daily for clinical symptoms of EAE. The WT and CD44-KO
animals displayed a similar onset and progression of the
disease, with ﬁrst clinical symptoms appearing around day 11
and peaking around day 18. However, the CD44-KO mice
exhibited signiﬁcantly increased disease severity as evi-
denced by clinical disease scores, disease index, andmortality
(Figure 1, AeC, and Table 1). A recent study suggested
diminished EAE severity in CD44-KO mice.42 To conﬁrm
ourﬁndings and identify reasons for this discrepancy,we used
several additional EAE immunization protocols, including
the identical protocol of that study, as well as using a distinct
and independently derived strain of CD44-KO mice.25,27
Under each circumstance, we found increased EAE disease
severity in the CD44-KO strain compared toWT counterparts
(Supplemental Figure S1 and Supplemental Table S1).
To evaluate quantities of immune cell within the CNS
parenchyma, brain and spinal cord tissue was isolated from
WT and CD44-KO animals near the peak of disease.
Immunoﬂuorescent analysis revealed signiﬁcantly increased
numbers of immune cells (CD45þ) in the spinal cords of the
CD44-KO animals compared to WT that was further
corroborated using H&E staining (Figure 1D). Compared to
WT, there were also greater numbers of CD4 T cells found
in the spinal cords of CD44-KO by immunoﬂuorescence
(Figure 1E). On average, 1.20  106 mononuclear cells1325
Figure 1 CD44-KO mice suffer from increased EAE disease severity and show enhanced disease characteristics. A: Average clinical disease scores of WT and
CD44-KO mice following induction of EAE, where mortality scores are included in average score from time of death throughout the study. Data represent two
independent experiments with combined nZ 21 for WT, nZ 18 for CD44-KO. Data are expressed as means SEM. B: Clinical disease curve, wheremortality scores
are included in average score only on day of death and excluded from subsequent days. yCD44-KO death. C: Kaplan-Meier survival curve.D: RepresentativeH&E stain
(left panels) and CD45 immunoﬂuorescence (right panels) of WT (top row) and CD44-KO (bottom row) lumbar spinal cord,4magniﬁcation, at day 20 (nZ 3 for
each). Arrows indicate inﬂammatory inﬁltrates; Regions indicated by yellow arrows and insets are shown at higher magniﬁcation (20). E: Representative CD4
immunoﬂuorescence of WT and CD44-KO lumbar spinal cord at day 20 (nZ 3 for each). F: Real-time PCR analysis of mononuclear cell RNA isolated from inﬂamed
CNS (day 20) for immune cell markers and cytokines. Six spinal cords were pooled for each strain sample, and samples were run in triplicate. Data are presented as
DDCt fold change. G: Measurement of relative levels of anti-MOG antibody by ELISA. Data are presented as means  SEM with nZ 4 per group. *PZ 0.001.
Flynn et alwere isolated from the inﬂamed WT CNS, whereas 1.84 
106 were isolated from the CD44-KO. Quantitative real-time
PCR analysis of RNA isolated from these cells showed
greater quantities of lymphoid and activated microglial/
macrophage cells (CD3e, CD68) and cytokine mRNAs
(Figure 1F).
Finally, serum collected from WT and CD44-KO mice
was assessed for relative levels of total anti-MOG IgG at
day 0 (pre-immune, naïve), day 9, and day 18. No signiﬁ-
cant differences were observed between the WT and KOTable 1 EAE Clinical Disease Characteristics
Mouse strain
Average day
disease onset
Average maximum
disease score
WT 12.6 2.80*
CD44-KO 12.7 4.18*
EAE disease measurements from WT and CD44-KO mice. Disease index, a measu
mean daily disease score/mean day onset)  100.
*P Z 0.0003, **P < 0.0001.
1326IgG production in the naïve or early disease state. However,
by day 18, the CD44-KO mice had signiﬁcantly more serum
anti-MOG IgG than the WT mice (Figure 1G).
CD44-KO Mice Have Increased Proinﬂammatory T-Cell
Proﬁles during EAE
CD4 T cells are critical initiators and mediators of EAE. We
examined the characteristics of the T cells in the periphery
to identify potential causes of the increased inﬂammation inSum daily average
disease score
Disease index
(40 day)
Percent
mortality
67.11 494.47** 0
109.42 798.32** 61
re of when and how sick the animals become, is calculated by (sum of the
ajp.amjpathol.org - The American Journal of Pathology
Anti-Inﬂammatory Role of CD44 in EAEthe CD44-KO CNS. In the naïve state, the T-cell pop-
ulations (Figure 2A), as well as their MOG-speciﬁc cytokine
production (data not shown), were comparable between the
two strains.
When we examined splenic cytokine production in
response to MOG stimulation at several times during the
course of the disease (days 9, 15, 18, and 28), we found
signiﬁcantly increased production of Th17-associated cyto-
kines, strongly suggesting a greater number of Th17 cells, in
the CD44-KO throughout the duration of the disease
(Figure 2B). Further, a trend toward increased proin-
ﬂammatory cytokine IFN-g was also observed.
We postulated that the increased proinﬂammatory milieu
observed in the CD44-KO could be the result of impaired
immune suppression owing to decreased numbers or func-
tion of Tregs. Importantly, the CD44-KO mice had signiﬁ-
cantly lower numbers of splenic Tregs throughout the
disease (Figure 2C).
CD44-KO CD4 T Cells Express Lower Levels of TGFbRI
and Exhibit Altered CD4 T-Cell Polarization in Vitro
The paucity of splenic Tregs in CD44-KO mice during
EAE, despite similar numbers before disease induction
(Figure 2, A and C), suggested a potential defect in iTreg
differentiation. We postulated that this paucity could be due
to defective TGF-b signaling and/or increased Th17 pop-
ulations. Because no differences were noted in TGF-b
cytokine levels (Figure 2B), we examined surface protein
expression of the three TGF-b receptors (TGFbR) on WT
and CD44-KO splenocytes. No appreciable difference wasFigure 2 CD44-KO mice produce greater amounts of proinﬂammatory cytokines
WT mice during EAE. A: WT and CD44-KO mice contain similar numbers of thymocy
FACS. Tregs are identiﬁed as CD4þCD25þFoxP3þ cells. CD4þCD69þ cells are gated o
nZ 6 per strain and are expressed means SEM. B: Splenocytes isolated from imm
Ag induction of cytokines was measured via ELISA. Splenocytes were isolated ind
supernatant was run in triplicate. Data are expressed as means  SEM. IFN-g leve
analysis of splenic CD4þCD25þFoxP3þ regulatory T cells during EAE. For each day,
means  SEM. *P < 0.01, **P < 0.005, and ***P < 0.0001.
The American Journal of Pathology - ajp.amjpathol.orgobserved in TGFbRII or TGFbRIII expression (data not
shown). However, the CD44-KO splenocytes showed
signiﬁcantly lower expression of TGFbRI, both at the cell
surface as detected by FACS (Figure 3A) and in whole-cell
lysates as detected by Western blot (Figure 3B). The
decreased expression was speciﬁc to CD4 T cells, as no
signiﬁcant differences were seen when comparing CD4 T-
celledepleted samples (Figure 3B). Further, despite differ-
ence in TGFbRI protein expression, there was no alteration
in mRNA level (Figure 3C).
Lower expression of TGFbRI could alter TGF-b signaling,
leading to aberrant Treg polarization and loss of iTregs
in vivo. However, because TGF-b signaling is also required
for the differentiation of Th17 cells, it is possible that CD44-
KO cells have abnormal polarization to this effector subtype
as well, which could also prevent appropriate Treg differ-
entiation. To test these theories, we isolated naïve CD4 T
cells and subjected them to Treg or Th17 polarizing condi-
tions in vitro. WT and CD44-KO CD4 T cells showed similar
TGF-b dose-dependent increases in Treg differentiation.
However, the CD44-KO cells showed a signiﬁcantly
enhanced polarization to the Th17 phenotype compared to
WT (Figure 4). Small amounts of Treg differentiation
occurred under Th17 polarizing conditions in both WT and
CD44-KO samples, but no signiﬁcant differences were
observed in this population (data not shown). Under Treg-
polarizing conditions, there was no induction of Th17 cells
in WT CD4 T cells, though a slight increase was observed in
the Th17 population in the CD44-KO CD4 T cells.
To determine whether addition of CD44 ligand altered the
development of Th17 cells, we examined Th17 polarization, especially those associated with Th17 cells, and lower number of Tregs than
tes and splenocytes, with similar cell-type distribution in the naïve state by
n CD4. Data are representative of two independent experiments with a total
unized animals at indicated day were stimulated with MOG35e55 peptide, and
ependently from six animals per strain at indicated time points, and each
ls on days 18 and 28 are on a distinct scale in pg/mL. C: Quantitative FACS
splenocytes were isolated from six animals per strain. Data are expressed as
1327
Figure 3 CD4 T cells from CD44-KO mice express lower surface and total
TGFbRI protein despite similar amounts of mRNA. A: FACS analysis of total
splenocytes (left panel) and CD4þ T cells (right panel) for surface TGFbRI.
Histograms are representative of two independent experiments, with
combined nZ 8. Median ﬂuorescence intensity for CD4 T-cell TGFbRI: WTZ
20.7 3.2, and CD44-KOZ 9.1 0.4. PZ 0.006.B: Western blot analysis of
TGFbRI total protein expression in total splenocytes (spl), CD4þ T cells (CD4),
and splenocytes depleted of CD4þ T cells (spl w/o CD4) (top panel) and
densitometry quantiﬁcation (bottom panel). Lysates were generated from
three animals per strain. Data are expressed as  SEM C: Real-time PCR
quantiﬁcation of TGFbRI from WT and CD44-KO CD4þ T cells subject to DDCt
analysis. Data are expressed as means  SEM, nZ 6 per strain. *PZ 0.05,
**PZ 0.02.
Flynn et alin the presence of HA, the best-characterized CD44 ligand.
No statistically signiﬁcant changes in Th17 polarization
were observed in response to LMW or HMW HA treatment
compared to culture in the absence of LMW or HMW HA
(Figure 4B).
Increased EAE Severity Results from Loss of CD44 on
BM-Derived and Stromal Cells
Because CD44 is ubiquitously expressed, we tested the
possibility that CD44 expression on cells other than, or in
addition to, circulating immune cells may also be important
in EAE. To do so, BM-chimeric mice were generated
by transfer of WT or CD44-KO BM into lethally irradiated
WT or CD44-KO recipients. FACS analysis of CD44
expression in inguinal lymph node and splenic cells was
used to determine the degree of chimerism in the lymphatic
system of these mice. WT or CD44-KO mice that received
WT BM (WT/WT and WT/KO, respectively) contained
mostly WT immune cells (CD45þ, CD44þ), whereas WT or
CD44-KO mice that received CD44-KO BM (KO/WT
and KO/KO, respectively) contained mostly CD44-KO1328immune cells (CD45þ, CD44) (Figure 5, AeD). Further,
FACS analysis of the microglial population (CD11bþ,
CD45lo) in the chimeric mice revealed that microglia from
KO/WT and KO/KO chimeras lacked CD44 expression
while WT/KO and WT/WT microglia expressed CD44
(Figure 5E). Thus, resident microglia were replaced by
circulating donor cells following irradiation, as has been
described previously.43
Next, EAE was examined in chimeric mice. As expected,
and consistent with our previous experiments, the WT/WT
mice had the least severe disease and lowest mortality rate,
and the KO/KO mice had the highest disease severity and
mortality rate. However, KO/WTmice andWT/KOmice
both exhibited greater disease and mortality than WT/WT
mice, and less disease and mortality than KO/KO mice
(Figure 5, FeH, and Table 2). These data suggest that CD44
expression on both radiation-sensitive and -insensitive
cells had an effect on disease severity. Further, though the
surviving WT/KO mice had similar disease severity as the
surviving KO/WT mice, the former showed a recovery
that more closely followed the WT/WT chimeras, whereas
the KO/WT had a lower overall mortality rate than the
WT/KO group.
CD44-KO BrEC Support Enhanced T-Cell Adhesion and
Transmigration
We investigated the possibility that loss of CD44 expression
on radiation-insensitive EC of the blood vessels could result in
increasedT-cell adhesion or transendothelialmigration,which
could contribute to increased inﬂammation. Using WT and
CD44-KO lymphocytes and low-passage immortalized mur-
ine BrEC, we examined the ability of resting or activated T
cells to adhere to and transmigrate across quiescent or TNFa-
stimulated BrEC monolayers. WT and CD44-KO BrEC both
lacked P-selectin expression and expressed similar levels of
adhesionmolecules intercellular adhesionmolecule 1 (ICAM-
1), ICAM-2, vascular cell adhesionmolecule (VCAM), andE-
selectin (data not shown). Lymphocyte activation greatly
facilitated adhesion, whereas TNFa stimulation of the BrEC
appeared to be dispensable (Figure 6A). Therefore, only
activated lymphocytes and unstimulated BrEC were used for
the transmigration assays. There was signiﬁcantly greater
T-cell adhesion to, and migration across, the CD44-KO BrEC
monolayer, compared to the WT BrEC monolayer, regardless
of CD44 expression on the T cells (Figure 6, A and B).
Theoretically, lymphocyte adhesion can be affected by
alterations in the endothelial glycocalyx, a network of
membrane-bound glycoproteins and proteoglycans lining
the endothelium luminally.43,44 HA, typically anchored to
EC by CD44, is a critical component of the glycocalyx. To
identify the role of HA in adhesion in this system, we
examined T-celleEC adhesion following treatment of WT
and CD44-KO EC with hyaluronidase (Figure 6C). Hyal-
uronidase treatment had no effect on lymphocyte (WT or
CD44-KO) adhesion to WT EC. Although treatment ofajp.amjpathol.org - The American Journal of Pathology
Figure 4 Naïve CD44-KO CD4þ T cells have
a similar capacity to polarize to the Treg pheno-
type, but have enhanced polarization to the Th17
phenotype as WT CD4þ T cells in vitro. Equivalent
numbers of naïve CD4þ T cells were subjected to
Treg (A) or Th17 (B) polarizing conditions in vitro.
Polarization to these phenotypes was quantiﬁed
via FACS analysis, and representative dot plots for
each polarization are included below each graph.
Data are representative of one of two (LMW/HMW
HA Th17 conditions) or three (all other conditions)
independent experiments with naïve CD4þ T cells
isolated from a total of six (LMW/HMW HA Th17
conditions) or nine (all other conditions) mice per
strain and are expressed as means  SEM. *P 
0.05, **P  0.02.
Anti-Inﬂammatory Role of CD44 in EAECD44-KO EC monolayers with hyaluronidase reduced
lymphocyte adhesion to levels observed on WT monolayers,
we could not detect a difference in total HA abundance
between WT and CD44-KO EC or spinal cords using
immunohistochemistry (Supplemental Figure S2).
The CD44-KO Brain Vasculature Is More Permeable than
WT in Naïve and Disease States
We next questioned whether there was differential BBB
permeability in the CD44-KO mice, another endothelial
defect that could promote increased inﬂammation. Intrave-
nous injections of Evans Blue dye were used to assess
vascular permeability of several vascular beds in vivo. In
an unchallenged state, no permeability differences were
observed in the inguinal lymph node blood vessels, dermal
microvasculature, hepatic vasculature, or pulmonary vascu-
lature. However, the cerebral vasculature of CD44-KO miceThe American Journal of Pathology - ajp.amjpathol.orgwas signiﬁcantly more permeable than in WT mice
(Figure 7A). Immunostaining for IgG, which is larger than
Evans Blueebound albumin and is also excluded from EC
junctions, further corroborated these results. The WT brain
was devoid of IgG, whereas the CD44-KO brain had exten-
sive IgG inﬁltration that localized to perivascular tissues
(Figure 7B).
The integrity of the CNS vasculature was then assessed
throughout EAE. The CD44-KO mice showed a sustained,
though subtler, increase in permeability throughout the
disease, which returned to baseline in the chronic stage of
the disease (Figure 7C). During the course of EAE skin
vessel permeability was unaffected, illustrating the speci-
ﬁcity of the response.
We next examined the architecture of the different BBB
structural components to identify the level at which the BBB
is permeable in CD44-KOmice. Using immunoﬂuorescence,
we examined the localization of IgG in the brain of CD44-1329
Figure 5 Increased EAE disease severity in CD44-KO mice is due to loss of CD44 on circulating and noncirculating cell types. BM chimeras were generated
using WT or CD44-KO donor BM and WT or CD44-KO recipients, and subjected to EAE (BM donor/Recipient). A and C: Representative dot plots of FACS analysis
of CD44 expression by immune cells (CD45þcells) in inguinal lymph node cells (A) and splenic cells (C) from BM chimeric mice. B and D: Average percentage of
CD45þ cells expressing or lacking CD44 isolated from chimeric mouse inguinal lymph node (B) or spleen (D). Data are expressed as means  SEM: nZ 4 for
each chimeric group. E: Microglia (CD11bþCD45lo) were isolated from BM-chimeric mice. Gated region represents the microglial population. Histograms
represent CD44 expression within the microglial-gated population. F: Kaplan-Meier survival curve of chimeric animals throughout EAE. G: Clinical disease curve
of chimeric animals with mortality scores included in average score from time of death throughout the remainder of the study. H: Clinical disease curve of
chimeric animals with mortality scores included on day of death but excluded from average scores in subsequent days of study. Data are expressed as means 
SEM, from two independent experiments: n Z 16 WT/WT; n Z 18 all other groups.
Flynn et alKO mice with respect to EC marker CD31, endothelial
basement membrane component collagen IV (ColIV), and
astrocytic marker glial ﬁbrillary acidic protein (GFAP). IgG
was localized outside of EC CD31, but not astrocytic GFAP
(Figure 7, D and E). In some vessels, IgG was found outside
ColIV whereas in others, it appeared within the basement
membrane to EC junctions, due to the punctate nature of IgG
localization (Figure 7F).Discussion
During EAE, autoreactive lymphocytes become activated
and undergo differentiation in the periphery, migrate to the
CNS, and interact with BrEC to exit the vasculature and gain
access to the CNS parenchyma where they initiate inﬂam-
mation and disease. Our data suggest that CD44 is involved in
several of these processes as a negative regulator of1330inﬂammation with roles in CD4 T-cell differentiation, adhe-
sion and transendothelial migration, and BBB permeability.
The proinﬂammatory phenotype of the CD44-KO mice is
evidenced by increase in the following: clinical disease,
immune and CD4 T-cell numbers within the CNS, antibody
production, and a proinﬂammatory cytokine milieu. The
similar kinetics of disease progression between the WT and
CD44-KO suggests that the increased disease severity in the
CD44-KO could result from altered CD4 T-cell differenti-
ation, which could increase disease severity without aff-
ecting the disease time course. Despite similar cytokine
production in naïve animals, and similar CD4 T-cell
numbers and activation states (CD62Lþ and CD69þ) in the
periphery of immunized animals, the phenotypic proﬁle of
CD4 T cells was markedly different between the two strains
following disease induction.
Increased IL-17 production by CD44-KO splenocytes du-
ring EAE strongly indicated greater quantities of Th17 cells,ajp.amjpathol.org - The American Journal of Pathology
Table 2 BM Chimera EAE Clinical Disease Characteristics
Donor listed ﬁrst,
recipient second
Average day
disease onset
Average maximum
disease score
Sum daily average
disease score Disease index
Percent
mortality
WT/WT 13.92 2.73yyy 105.2 755.6yyy 7.00
CD44-KO/WT 12.88 4.09**yy 163.9 1273.3**yy 18.75
WT/CD44-KO 13.67 3.80*y 151.2 1106.7*yy 31.25
CD44-KO/CD44-KO 12.06 4.75*** 212.2 1758.69*** 68.75
EAE disease measurements from BM chimeric mice.
*P < 0.05, **P < 0.005, and ***P < 0.0001 versus WT/WT.
yP < 0.006, yyP < 0.0004, and yyyP < 0.0001 versus KO/KO.
Anti-Inﬂammatory Role of CD44 in EAEbecause IL-17 is predominantly a CD4 T-cell product.8,45
Further, the signiﬁcantly increased levels of IL-6 and IL-23,
though possibly produced by multiple cell types, also
support an increase in the Th17 population, because these
cytokines are required for Th17 maturation. Moreover, theFigure 6 CD44-KO BrEC monolayers support greater adhesion and
transmigration than do WT BrEC, regardless of T-cell expression of CD44. A:
Adhesion of nonactivated and polyclonally activated T cells to unstimulated
and TNFa-stimulated WT and CD44-KO conﬂuent BrEC monolayers. B:
Transmigration of polyclonally activated T cells through conﬂuent WT and
CD44-KO BrEC monolayers in the Transwell system. C: Adhesion of poly-
clonally activated T cells to unstimulated BrEC monolayers with and without
hyaluronidase treatment. *P  0.05, **P  0.007, and ***P  0.0001.
Average data are presented as means  SEM from three independent
experiments, n Z 9 for each condition.
The American Journal of Pathology - ajp.amjpathol.orgtrend for increased IFN-g production in the CD44-KO mice
further illustrates an augmented proinﬂammatory environment
in the CD44-KO despite similar levels of IL-10 and TGF-b,
both ofwhich have pro- and anti-inﬂammatory functions in the
immune system.46,47 These data are consistent with a proin-
ﬂammatory environment skewed toward Th17-associated
cytokine milieu in the CD44-KO mice.
Tregs control various aspects of the immune response,
including limiting activation and function of innate and
adaptive immune cells.48 Therefore, Tregs are critical medi-
ators of EAE; Tregs are involved not only in limiting
inﬂammation within the CNS, but also play a critical
suppressive role during priming in the peripheral compart-
ment. Further, peripheral Tregs from MS patients show
a decreased suppressive capacity.49 It is plausible that the
increased CNS inﬂammation, antibody production, and
proinﬂammatory cytokine production observed in the CD44-
KO mice are a result of defective immunosuppression by
Tregs in the peripheral compartment. We found reduced
numbers of Tregs in the periphery of CD44-KO mice
throughout the disease, and althoughwe did not examine Treg
suppressive function, previous studies have shown that CD44
expression correlates with superior Treg suppressive function
in both murine and human cells.50,51 Therefore, overall
suppression of inﬂammation during EAE could be impaired,
not only by a reduced number of Tregs, but also by reduced
Treg function in the CD44-KO mouse.
Though there are fewer Tregs in the CD44-KO spleen
following EAE induction, these mice have similar numbers of
naturally occurring Tregs in the naïve state asWTmice. Thus,
the reduced Treg population observed throughout the disease
is likely a consequence of defective generation or survival of
iTregs. Moreover, an increase in Th17 cells accompanies the
reduction of Tregs in the CD44-KO throughout the disease.
These cell types share a common developmental pathway, as
both require TGF-b for differentiation, but use different
downstream signaling components to achieve their different
phenotypic programs.52 Th17 differentiation is favored at
lower TGF-b concentrations, whereas Treg differentiation is
favored at higher concentrations.53 Conceivably, the
decreased TGFbRI expression on CD44-KO CD4 T cells
attenuates the TGF-b signal, or alters the ratio of TGFbRI
with other receptors, either of which could result in differ-
ential downstream signaling and altered polarization. In vitro,1331
Figure 7 The CD44-KO BBB is partially disrupted
because the cerebral vasculature, but not the astro-
cytic component, of the CD44-KO is signiﬁcantly more
permeable than WT to albumin and IgG before and
following immunization.A: Baselinepermeability was
determined using Evans Blue dye. For each vascular
bed, WT permeability indices were set equal to one,
and CD44-KO indices were calculated relative to WT
values. Data are expressed as means  SEM. B:
Immunoﬂuorescent images of vascular marker CD31
(green)andmurine IgG (red) innaïveWTandCD44-KO
brain. Top row, representative low-power images (4
magniﬁcation); bottom row, representative high-
power images (63 magniﬁcation) derived using
confocal microscopy. Images are representative of
three independent experiments. C: Evans Blue
permeability index in cerebral (lower panel) and
dermal (upper panel) vasculature post-EAE induc-
tion. Six animalswereused per strain, per disease day.
Data areexpressed asmeans SEM. *P 0.05, **P<
0.03. DeF: Representative high-power (63 magni-
ﬁcation) confocal immunoﬂuorescent images of three
independent experiments in naïve CD44-KO brain. D:
From left to right: CD31 (green), IgG (red), and
astrocytic marker GFAP (cyan) in vessel cross section.
Second-to-last image is the merger of CD31 and IgG,
and the right-most image is the merger of GFAP and
IgG. E: Longitudinal vessel brain vessel section; GFAP
(cyan), IgG (red) immunoﬂuorescence. F: Cross (left
panel) and longitudinal (right panel) vessel sections
for basement membrane component collagen IV
(green) and IgG (red). White arrows indicate IgG
localization outside collagen IV; yellow arrows indi-
cate IgG localized to endothelial junctions.
Flynn et alnaïve WT and CD44-KO CD4 T cells demonstrate an
equivalent polarization to Tregs in response to TGF-b, but
CD44-KO CD4 T cells have enhanced polarization to the
Th17 phenotype (which might have been greater if IL-23 had
been administered sequentially instead of simultaneously8).
Despite their common developmental pathway, Th17 and
Treg fates are mutually exclusive, and cytokines produced by
one inhibit, or even reverse, differentiation into the other.8,46
As such, it is possible that altered TGF-b signaling in the
CD44-KO tips the balance of T-cell differentiation toward
Th17, which in turn inhibits further iTreg generation, result-
ing in lower Treg numbers and a Th17-skewed proﬁle in vivo.
The reverse can also be true, where decreases in Th17 cells
are met with reciprocal increases in Treg, resulting in an
amelioration of EAE.54
Altered glycogen synthase kinase 3b (GSK3b) activation
and signaling could also be a contributing factor to enhanced
Th17 differentiation in CD44-KOT cells. Recently, inhibition
of GSK3b was shown to prevent in vitro Th17 differentia-
tion.55GSK3b is required for signal transducer and activator of
transcription 3 (STAT3) activation55 and also promotes
degradation of SMAD family member 3 (Smad3) in the
absence of TGF-b.56 Because STAT3 is required for Th17
differentiation,whereas Smad3 inhibits this process, it is likely
that both actions of GSK3b contribute to the generation of
Th17 cells. Interestingly, we have found increased activation1332of GSK3b in CD44-KO EC (unpublished data). Further,
changes in GSK3b activation could be related to alterations in
TGF-b signaling, as there is crosstalk between these signaling
pathways.57,58 In fact, TGF-b signaling can lead to inactiva-
tion of GSK3b.57 In the CD44-KO T cells, a plausible model
could be that differential TGF-b signaling, in the presence of
appropriate cytokines, leads to increased GSK3b activation,
which then promotes increased Smad3 degradation and
STAT3 activation, resulting in enhanced Th17 differentiation.
Further,GSK3b activation is not observed in response toTGF-
b alone or in iTregs.55 If GSK3b-dependent mechanisms are
responsible for alteredTh17generation inCD44-KOcells, this
could explain why no differences in iTreg polarization are
observed in vitro, whereas decreased iTreg generation in vivo
results from the increased numbers of Th17 cells. Finally,
active GSK3b is also required for inﬂammatory cell produc-
tion of IL-6.55,59 IL-6 is produced by innate immune cells
and Th17 cells, inhibits iTreg differentiation, and is produced
in greater quantities in CD44-KO splenocytes following
MOG35e55 stimulation. If GSK3b is indeed increased in
CD44-KO cells, this could be a potential explanation for the
increased IL-6 production as well.
It is a novel ﬁnding that CD44 regulates TGFbRI expres-
sion. Our data suggest that this regulation in CD4 T cells
occurs at the posttranscriptional level. Possibly, CD44 could
aid in stabilization of TGFbRI at the plasma membrane,ajp.amjpathol.org - The American Journal of Pathology
Anti-Inﬂammatory Role of CD44 in EAEpotentially through direct physical interaction, which has
been previously demonstrated in metastatic breast tumor
cells.60 Further, binding of HA to CD44 led to Smad3 acti-
vation, a downstream component in TGF-b signaling, which
is of particular interest because Smad3 inhibits Th17 differ-
entiation.52 This introduces the possibility that the potentially
altered TGF-b signaling in the CD44-KO could be a result,
not only of decreased TGFbRI, but also or alternatively, of
loss of interaction between CD44 and TGFbRI.
Our BM-chimeric EAE data illustrated that increased EAE
disease severity in the CD44-KO mice is due to loss of CD44
on both BM-derived and noneBM-derived cell types,
because any chimeric mice with both WT and CD44-KO
components showed intermediate disease severity compared
to those with only WT or CD44-KO components. It is inter-
esting that theWTmice receivingCD44-KOBM(KO/WT)
showed a chronic persistence of disease symptoms, whereas
the CD44-KO mice that received WT BM (WT/KO) eli-
cited a recovery, despite similar maximal disease severity
between these two chimeras. Conceivably, the former expe-
riences greater disease than a WT/WT chimera because
they contain CD44-KO T cells, and as such, experience the
same alterations in CD4 T-cell proﬁles, namely increased
numbers of Th17 cells and decreased numbers of Tregs. As
Tregs are involved in promoting resolution of EAE,12 as well
as limiting the inﬂammatory response, mice with reduced
numbers of Tregs, such as those with CD44-KO T cells,
would likely fail to exhibit disease recovery as well as having
greater clinical symptoms. The KO mice receiving WT BM
(WT/KO) by contrast contain a CD44-KO BBB, and as
such, experience increased BBB permeability, which may
allow greater quantities of immune cells to penetrate the CNS,
resulting in greater inﬂammation and disease, but maintain
sufﬁcient Tregs to elicit better recovery. The combination of
altered T-cell differentiation and increased BBB permeability
would likely result in the greatest disease, which is observed
in the KO/KO chimeric mice.
Though there are multiple potential noncirculating cells
types involved in EAE, including lymph node stromal cells
and CNS resident cells, we directed our focus on vascular
EC due to the crucial role of the vasculature in promoting
and limiting inﬂammatory processes. Endothelial loss of
CD44 promoted enhanced adhesion and migration of T cells
in vitro, because CD44-KO BrEC monolayers support
greater adhesion and transmigration than do WT BrEC
monolayers, regardless of T-cell expression of CD44.
In vivo, increased adhesion and transendothelial trans-
migration can in turn lead to increased immune cell
extravasation into the CNS parenchyma and a subsequent
increase in CNS inﬂammation. Classical adhesion mole-
cules, such as ICAM and VCAM, are likely not the cause
for increased adhesion, as CD44-KO BrEC express similar
levels of these molecules in the absence of TNFa. Though
TNFa stimulation increases expression of these molecules,
we did not observe increased adhesion in response to TNFa
in either cell type.The American Journal of Pathology - ajp.amjpathol.orgTheoretically, increased adhesion could result from
modiﬁcations to the endothelial glycocalyx, a network of
membrane-bound glycoproteins and proteoglycans lining the
endothelium luminally.43,44 HA, which can be anchored by
CD44, is a critical component of the glycocalyx, and due to its
length, is the only glucosaminoglycan capable of forming
entangled networks.61 Consequently, loss of HA from the EC
surface could result in decreased depth of this layer, rendering
other adhesive molecules more accessible, leading to greater
lymphocytic adhesion. Alternatively, increased HA levels
could also form a thicker, tangled, stickier mesh, allowing
easier entrapment of lymphocytes. To our surprise, we found
no effect of hyaluronidase treatment on lymphocyte adhesion
to WT EC. Even more surprising, treatment of CD44-KO EC
monolayers with hyaluronidase reduced lymphocyte adhe-
sion to the levels observed onWTmonolayers. This suggests
that HA is a contributing factor in the increased lymphocyte
adhesion in the absence of HA receptor CD44. One potential
explanation is that in the absence of CD44, EC use alternative
or compensatory HA receptors, such as receptor for hyalur-
onic acid-mediated motility (RHAMM), to tether HA to the
EC surface. In doing so, this could alter HA conformation or
signaling, arrangement and organization of the endothelial
surface layer, and regulation of cellular processes and
behaviors. For example, in collagen-induced arthritic CD44-
KO mice, cell migration and up-regulation of inﬂammatory
genes occurred via signaling through the RHAMM
pathway.32 It is also possible that loss of CD44 leads HA
accumulation, because CD44 is the most common endocytic
receptor for HA responsible for HA turnover. Animals with
conditional loss of CD44 within the dermis overaccumulated
HA in this tissue.62 Increased endothelial HA accumulation
could lead to a more adhesive endothelial glycocalyx.
However, immunohistochemical analysis revealed similar
levels of total HA in WT and CD44-KO spinal cord vessels
andBrEC (Supplemental Figure S2). Although no differences
were identiﬁed in total HA expression, immunohistochem-
istry is incapable of distinguishing between abundance of
HMW or LMW HA fragments, or between differential
molecular interactions or conformations, both of which may
be involved in adhesive events.
It remains possible that a differential molecular and elec-
trostatic composition of the endothelial surface layer may
contribute to increased lymphocytic adhesion. Many post-
translational modiﬁcations of CD44 produce negative
charges, and loss of CD44 could result in loss of electrostatic
charge repulsion between cells, resulting in greater adhesion.
However, further manipulation of the complex organization
of the endothelial surface layer was beyond the scope of this
study. Additionally, changes in endothelial chemokine pro-
duction could also affect lymphocyte-EC adhesion.63
Enhanced transendothelial migration can result from
increased T-celleEC adhesive interactions, decreased junc-
tional competency between EC,64 or increased protease64 or
chemokine production.63 CD44 could participate in one or
more of these processes, some of which are currently under1333
Flynn et alinvestigation in our laboratory. Increased permeability of the
CD44-KO BBB, suggesting loss of EC junctional compe-
tency, is at least one potential explanation for enhanced
transmigration. Further, CD44 has previously established
roles in matrix metalloproteinase (MMP) biology,65,66 which
are known to affect vascular permeability.67 Previous studies
from our laboratory have shown that dysregulation of BBB
permeability and MMP expression can lead to enhanced
lymphocyte transmigration and increased EAE severity.41,68
During the pathogenesis of EAE, the BBB is compro-
mised and becomes permeable to plasma proteins and
immune cells. Increased BBB permeability, such as that in
CD44-KO, would allow for intensiﬁcation of these pro-
cesses and increased inﬂammation. The inherent leakiness
in the naïve CD44-KO BBB is likely even further exacer-
bated throughout the disease by inﬂammatory cytokines,
such as IL-17, which enhance BBB permeability and are
produced in greater amounts in the CD44-KO.
The inherent partial disruption of BBB integrity in
unimmunized CD44-KO mice is a particularly fascinating
ﬁnding. The BBB is a dynamic functional and structural
component of the CNS, charged with the imperative task of
maintaining an appropriate CNS microenvironment.69 This
barrier is formed primarily by highly specialized EC, sur-
rounded by a complex basement membrane, invested by
pericytes, and ensheathed by astrocytic end-foot processes.
A complex crosstalk between glia, pericytes, BrEC, and
their extracellular matrices is critical for formation and
maintenance of BBB integrity and function. Thus, CD44
expression on multiple BBB cell types could affect the way
these components interact with one another and/or their
underlying extracellular matrix, leading to a disruption of
the appropriate intercellular communication necessary for
junctional integrity in the brain vasculature. This could
result from changes in direct contact between these cell
types, or altered expression of secreted molecules, such as
MMPs, from one or more of these cells. CD44, through its
numerous potential molecular interactions, has the capacity
to affect both in a myriad of ways. Though the exact
mechanism of BBB regulation by CD44 is beyond the scope
of the current study, these data have illustrated that EC
junctions are disrupted in the CD44-KO BBB. Though IgG
localizes outside the endothelial elements in the CD44-KO
brain, its localization within astrocytic processes suggests
it does not penetrate beyond the astrocytic component. It is
unclear how or why IgG does not permeate beyond the
astrocytic end feet in the CD44-KO brain. However, it is
clear that CD44 expression on BBB cells is required to
maintain EC junctional, and thus BBB, integrity. Loss of EC
junctional competency results from loss of molecular
cohesion at the EC border, subsequent to decreased adhe-
sive interactions between junctional molecules, or increased
barrier-disrupting agents, such as proteases, that cleave
junctional bonds directly or disrupt the underlying matrix
that supports the maintenance of these interactions. These
processes are dependent on the complex molecular crosstalk1334between BBB components and can be regulated by CD44
interactions in various ways as described above. Addition-
ally, these ﬁndings may have important implications in
future BBB permeability studies. Permeability needs to be
assessed on various levels because permeability of one, but
not all, levels of the BBB could result in different biological
consequences, and not all assays are capable of dis-
tinguishing between total and partial barrier disruption.
It is also important to note that we cannot conclude
increased leakage of Evans Blue into the CNS relative to
other tissues, but only in the CD44-KO CNS compared to the
WT CNS. Using Evans Blue, it is not possible to compare
permeability of one organ to another. Because the dye is
extracted in formamide, and parenchymal beds have differ-
ential compositions, the resulting turbidity differences
between organ samples cause skewed spectrophotometric
absorbance values. For example, myelin within the CNS
causes relatively higher turbidity and absorbance values than
vascular beds such as the skin that lack such components.
Our ﬁndings that CD44 acts as a negative regulator of
inﬂammation in EAE are consistent with increased inﬂam-
mation observed in various experimental models in CD44-
deﬁcient mice. While the current study was underway, Guan
et al42 reported that CD44-KOmice showed diminished EAE
severity that correlated with more anti-inﬂammatory CD4 T-
cell proﬁles and differentiation in vivo and in vitro. The
reasons for the discrepancies between Guan et al42 and our
work are unclear. In an attempt to understand these differ-
ences, we used several EAE induction protocols, including
that of Guan et al, and have found in all circumstances that the
CD44-KO mice succumb to more severe disease than do WT
mice (Supplemental Figure S1 and Supplemental Table S1).
Further, though these data are derived from mice from the
Jackson Laboratory, we observed similar disease progression
in a separate and independently derived CD44-KO strain that
was a gift from Dr. Paul W. Noble25,27 (Supplemental
Figure S1 and Supplemental Table S1).Conclusions
In summary, CD44 is a complex multifunctional molecule
that can differentially regulate various cellular processes
depending on cell type, isoform expression, posttrans-
lational modiﬁcation, and interacting ligand. Here, we have
identiﬁed several mechanisms of EAE that are altered in the
absence of CD44, leading to exacerbated disease. Mecha-
nistic understanding of how CD44 alters each process is still
under investigation and must take into consideration the
heterogeneity of the CD44 family. Nonetheless, our data
from CD44-deﬁcient mice illustrate a role for CD44 in
limiting inﬂammation in EAE through several mechanisms
that might be applied to other immune diseases as well.
Speciﬁcally, we have identiﬁed novel roles for CD44 in
regulating the CD4 T-cell expression of TGFbRI, CD4
T-cell differentiation, and BBB integrity.ajp.amjpathol.org - The American Journal of Pathology
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